Seeking Alpha

ALX Oncology anticipates $2B–$4B HER2/CD47 breast cancer market opportunity while advancing biomarker-driven strategies

The company reiterated that the ASPEN-Breast Phase II trial is "on track to dose its first patient this quarter," with interim data expected in Q3 2026. ALX2004 initial safety data is expected in the ...

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of ...
KTLA

ImmuneOncia Announces Interim Results from Phase 1b Clinical Trial of Next-Generation CD47 Antibody 'IMC-002' at ASCO 2025

CHICAGO, June 2, 2025 /PRNewswire/ -- ImmuneOncia Therapeutics, Inc. (CEO Heung-Tae Kim) announced interim results today from the ongoing Phase 1b clinical trial of its next-generation CD47-targeting ...
Morningstar

Bitterroot Bio Announces Dosing of First Patient in MATADOR Phase 2a Study of BRB-002, an Immunomodulating Therapy Targeting CD47 in Atherosclerotic Cardiovascular Disease

BRB-002 is a novel, investigational, immunomodulating protein therapy that targets CD47 as a potential treatment option for patients with atherosclerotic cardiovascular disease (ASCVD). By targeting ...
BioWorld

Dual, tumor-specific TNFR2 and CD47 blockade using an oncolytic virus enhances anticancer immunity

Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide. Recent advancements in immunotherapy have demonstrated the potential of targeting immune checkpoints and ...
The Business Journals

Peninsula biotech company sets two clinical trials to revive its cancer-fighting fortunes

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company raised hundreds of ...